Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.

[1]  Sylvie Négrier,et al.  Imaging , Diagnosis , Prognosis Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma : Results from the International Kidney Cancer Working Group , 2011 .

[2]  R. Figlin,et al.  Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Motzer,et al.  Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients , 2010, Cancer.

[4]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. White,et al.  Imputing missing covariate values for the Cox model , 2009, Statistics in medicine.

[7]  M. Kattan,et al.  Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma , 2008, Cancer.

[8]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[9]  T. Choueiri,et al.  Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy , 2007, Cancer.

[10]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[11]  R. Bukowski,et al.  Prognostic Factors in Patients with Advanced Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[12]  R. Motzer,et al.  Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[13]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[15]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[16]  John Van Hoewyk,et al.  A multivariate technique for multiply imputing missing values using a sequence of regression models , 2001 .

[17]  R. Motzer,et al.  Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Rubin.  Multiple Imputation After 18+ Years , 1996 .

[20]  R. Sugden.  Multiple Imputation for Nonresponse in Surveys , 1988 .

[21]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[22]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.